Delivery Order SPE2DB24D1205-SPE2DB25FCZZU
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,287.88 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 mL auto-injector pens on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a $5,755.68 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. This is a non-set-aside, competitively awarded contract with performance completion targeted for August 12, 2025, with fulfillment occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's broader...
- The U.S. Department of Defense Medical Supply Chain awarded a $6,235.68 delivery order to AmerisourceBergen Drug Corp for Actemra ActPen 162 mg/0.9 ml auto-injectors. This firm fixed-price, non-set-aside contract was executed on August 11, 2025, with an ultimate completion date of August 12, 2025. The award represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injector units. This firm fixed-price delivery order, valued at $6,863.64, represents a competitive award with no set-aside designation and is scheduled for completion by August 21, 2025. The award was issued to AmerisourceBergen's Corporate Office division, with performance to take place at the company's...
- The Defense Logistics Agency awarded a delivery order valued at $32,838.00 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector pens. The contract, executed on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will be fulfilled from the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a delivery order valued at $4,575.76 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector pens. This firm fixed-price delivery order, issued on August 29, 2025, is set to be completed by September 2, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract was competitively awarded without set-aside restrictions, reflecting the contractor's demonstrated...
- The Defense Logistics Agency awarded a delivery order valued at $4,109.19 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 ml auto-injector pens. This firm fixed-price, non-set-aside contract was awarded on August 22, 2025, with an ultimate completion date of August 25, 2025. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a small-value transaction executed under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $38,677.92 to AmerisourceBergen Drug Corp for Actemra ActPen 162 mg/0.9 mL auto-injectors. This firm fixed-price delivery order, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a non-competitive award under the company's existing indefinite delivery contract with DLA. The pharmaceutical product will be delivered to AmerisourceBergen's corporate headquarters location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injector pens with a ceiling value of $12,969.00 and firm fixed pricing. This is a non-set-aside, competitively awarded contract with an ultimate completion date of August 25, 2025. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $18,202.15 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injectors. This firm fixed price delivery order, awarded on August 4, 2025, with an ultimate completion date of August 5, 2025, represents a competitive award with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, supporting the company's role as a...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZZUDelivery Order
The Defense Logistics Agency awarded a $21,626.20 delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. This firm fixed-price delivery order, with an ultimate completion date of September 2, 2025, represents a competitive award with no set-aside designation. The pharmaceutical product will be delivered to the Place of Performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order falls under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.999 billion vehicle designated SPE2DX and running through December 2026, which serves as a comprehensive global pharmaceutical support arrangement for military healthcare programs. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor that supplies a comprehensive range of medical products to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's federal contract portfolio demonstrates extensive experience fulfilling diverse pharmaceutical requirements across multiple therapeutic domains, ranging from specialty medications and vaccines to medical devices and diagnostic supplies. This delivery order for Actemra, a biologic treatment commonly used for rheumatoid arthritis and other autoimmune conditions, exemplifies the company's role in supporting military medical supply chains with both brand-name medications and specialized healthcare commodities essential to troop readiness and veteran healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.6k | 8/29/25 |